Characterization of a novel ATP-sensitive K + channel opener, A-251179, on urinary bladder relaxation and cystometric parameters

British Journal of Pharmacology

Volumn 151, Issue 4, 2007, Pages 467-475

  Shieh, C C ^a   Brune, M E ^a   Buckner, S A ^a   Whiteaker, K L ^a   Molinari, E J ^a   Milicic, I A ^a   Fabiyi, A C ^a   Daza, A ^a   Brioni, J D ^a   Carroll, W A ^a   Matsushita, K ^b   Yamada, M ^b   Kurachi, Y ^b   Gopalakrishnan, M ^a  

^a ABBOTT LABORATORIES   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

A 251179; ATP sensitive K + channels; Bladder; Incontinence; Kir6.2; Overactive bladder; Potassium channel; Potassium channel opener; SUR2A; SUR2B

Indexed keywords

4 METHYL N [2,2,2 TRICHLORO 1 (3 PYRIDIN 3 YLTHIOUREIDO)ETHYL]BENZAMIDE; A 251179; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BENZAMIDE DERIVATIVE; CARBACHOL; GLIBENCLAMIDE; PINACIDIL; POTASSIUM CHANNEL STIMULATING AGENT; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; URETHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; CONTROLLED STUDY; CYSTOMETRY; CYTOMETRY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; MEMBRANE POTENTIAL; MICTURITION; NEUROGENIC BLADDER; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; THORACIC AORTA; URODYNAMICS; WHOLE CELL;

ANIMALS; BENZAMIDES; FEMALE; GUINEA PIGS; MALE; MEMBRANE POTENTIALS; MUSCLE RELAXATION; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SWINE; URINARY BLADDER;

EID: 34250169056     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707249     Document Type: Article

References (42)

1. ATP channels. Physiol Rev 78: 227-245.
2. ATP channels and insulin secretion: a key role in health and disease. Biochem Soc Trans 34: 243-246.
3. Atwal KS, Grover GJ, Ferrara FN, Ahmed SZ, Sleph PG, Dzwonczyk S et al. (1995). Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranylcyanoguanidines: modification of the benzopyran ring. J Med Chem 38: 1966-1973.
4. Brading AF (1997). A myogenic basis for the overactive bladder. Urology 50: 57-67; discussion 68-73.
5. Brune ME, Fey TA, Brioni JD, Sullivan JP, Williams M, Carroll WA et al. (2002). (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quin olin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. II. in vivo characterization. J Pharmacol Exp Ther 303: 387-394.
6. Buckner SA, Milicic I, Daza AV, Coghlan MJ, Gopalakrishnan M (2002). Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics and sensitivity to potassium channel modulators. Br J Pharmacol 135: 639-648.
7. + channels in the pig and human detrusor. Eur J Pharmacol 400: 287-295.
8. Busija DW, Lacza Z, Rajapakse N, Shimizu K, Kis B, Bari F et al. (2004). Targeting mitochondrial ATP-sensitive potassium channels-a novel approach to neuroprotection. Brain Res Brain Res Rev 46: 282-294.
9. Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE et al. (2004). Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172: 1919-1924.
10. + channels. In: Triggle DJ, Gopalakrishnan M, Rampe D, Zheng W (eds). Voltage-Gated Ion Channels as Drug Targets. Wiley-VCH, Verlag GmBH & Co., KGaA, Weinheim, pp 335-354.
11. ATP opener that selectively inhibits spontaneous bladder contractions. J Med Chem 47: 3163-3179.
12. 3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs 13: 1493-1500.
13. Dawson CM, Croghan PC, Scott AM, Bangham JA (1986). Potassium and rubidium permeability and potassium conductance of the beta-cell membrane in mouse islets of Langerhans. Q J Exp Physiol 71: 205-222.
14. Fabiyi AC, Gopalakrishnan M, Lynch III JJ, Brioni JD, Coghlan MJ, Brune ME (2003). In vivo evaluation of the potency and bladder-vascular selectivity of the ATP-sensitive potassium channel openers (-)-cromakalim, ZD6169 and WAY-133537 in rats. BJU Int 91: 284-290.
15. Foster CD, Fujii K, Kingdon J, Brading AF (1989a). The effect of cromakalim on the smooth muscle of the guinea-pig urinary bladder. Br J Pharmacol 97: 281-291.
16. Foster CD, Speakman MJ, Fujii K, Brading AF (1989b). The effects of cromakalim on the detrusor muscle of human and pig urinary bladder. Br J Urol 63: 284-294.
17. Gopalakrishnan M, Buckner SA, Whiteaker KL, Shieh CC, Molinari EJ, Milicic I et al. (2002). (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quin olin-8(4 H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization. J Pharmacol Exp Ther 303: 379-386.
18. Gopalakrishnan M, Shieh CC (2004). Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders. Expert Opin Ther Targets 8: 437-458.
19. ATP expressed in guinea pig bladder smooth muscle cells. J Pharmacol Exp Ther 289: 551-558.
20. Greenland JE, Brading AF (1997). The in vivo and in vitro effects of hypoxia on pig urethral smooth muscle. Br J Urol 79: 525-531.
21. Grover GJ, Garlid KD (2000). ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol 32: 677-695.
22. Hashitani H, Brading AF (2003). Ionic basis for the regulation of spontaneous excitation in detrusor smooth muscle cells of the guinea-pig urinary bladder. Br J Pharmacol 140: 159-169.
23. 2+ channels and ryanodine receptors in guinea-pig urinary bladder myocytes. J Physiol 541: 483-492.
24. ATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270: 1166-1170.
25. + channel. J Biol Chem 271: 24321-24324.
26. Kumar V, Templeman L, Chapple CR, Chess-Williams R (2003). Recent developments in the management of detrusor overactivity. Curr Opin Urol 13: 285-291.
27. Lam TK, Pocai A, Gutierrez-Juarez R, Obici S, Bryan J, Aguilar-Bryan L et al. (2005). Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 11: 320-327.
28. ATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev 24: 213-266.
29. ATP channel openers. Curr Top Med Chem 6: 1031-1047.
30. + channel openers: in vitro pharmacological characterization. FASEB J 18: A169.3.
31. Perez-Medrano A, Buckner SA, Coghlan MJ, Gregg RJ, Gopalakrishnan M, Kort ME et al. (2004). Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder. Bioorg Med Chem Lett 14: 397-400.
32. ATP channels control hepatic glucose production. Nature 434: 1026-1031.
33. Quayle JM, Nelson MT, Standen NB (1997). ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77: 1165-1232.
34. + currents in neurons of the dorsal root ganglion of the adult rat. J Pharmacol Exp Ther 310: 159-168.
35. ATP channel openers structurally related to (+/-)-cromakalim. J Med Chem 49: 4690-4697.
36. Seino S (1999). ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 61: 337-362.
37. + channels in bladder smooth muscle cells. J Pharmacol Exp Ther 296: 669-675.
38. + channels by pinacidil and nicorandil. Br J Pharmacol 124: 985-991.
39. Wojdan A, Freeden C, Woods M, Oshiro G, Spinelli W, Colatsky TJ et al. (1999). Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat. J Pharmacol Exp Ther 289: 1410-1418.
40. + channel. J Physiol 499: 715-720.
41. ATP channel opener, on bladder hyperactivity and spinal c-fos expression evoked by bladder irritation in rats. Brain Res 807: 11-18.
42. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S (2004). Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171: 2311-2315.